Last reviewed · How we verify
NCT03482921
Body Parameters as an Independent Predictor of Acute Pancreatitis
trial in Acute Pancreatitis in 1,662 participants. Completed in 22 March 2018.
12 February 2018
Quick facts
| Lead sponsor | Ningbo No. 1 Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,662 |
| Start date | 1 December 2017 |
| Primary completion | 12 February 2018 |
| Estimated completion | 22 March 2018 |
| Sites | 1 location across China |
Conditions studied
- Acute Pancreatitis — all drugs for Acute Pancreatitis →
Sponsor
Ningbo No. 1 Hospital
Who can join
Adults 18 to 100, any sex, with Acute Pancreatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to assess the predictive significance of visceral adipose tissue (VAT) and visceral adipose tissue /skeletal muscle tissue ratio (VAT/SMT ratio) for the prognosis in acute pancreatitis (AP) patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of visceral adiposity on severity of acute pancreatitis: a propensity score-matched analysis.
Xie J, Xu L, Pan Y, Li P, et al · · 2019 · cited 28× · PMID 31195984 · DOI 10.1186/s12876-019-1015-z
Verify or expand the search:
- PubMed search for NCT03482921
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Pancreatitis
Currently open trials in the same condition.
- NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
- NCT06899087 — DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis · recruiting
- NCT07322978 — Incidence of Splanchnic Venous Thrombosis in Acute Pancreatitis and it's Correlation With Severity of Pancreatitis · recruiting
- NCT03547232 — Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial) · Phase 4 · recruiting
- NCT06401577 — Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics · recruiting
Other Ningbo No. 1 Hospital trials
Trials by the same sponsor.
- NCT07181759 — Clinical Trial of VISOR vs fURS for Upper Urinary Tract Stone · NA · not yet recruiting
- NCT07001865 — Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia · enrolling by invitation
- NCT06984510 — Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population · recruiting
- NCT06905795 — Screening and Intervention of MASLD in Children · NA · active not recruiting
- NCT06987760 — Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03482921 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ningbo No. 1 Hospital
- Last refreshed: 29 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03482921.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing